Rashmi Chugh

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi request reprint Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model
    Rashmi Chugh
    1500 E Medical Center Dr, C407 Med Inn, SPC 5843, Ann Arbor, MI 48109 5843, USA
    J Clin Oncol 27:3148-53. 2009
  2. doi request reprint Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial
    Rashmi Chugh
    Department of Internal Medicine, University of Michigan, Ann Arbor, 48109 5843, USA
    Clin Cancer Res 16:4884-91. 2010
  3. doi request reprint Pharmacotherapy of sarcoma
    Rashmi Chugh
    University of Michigan, C407 Med Inn Building, 1500 E Medical Center Dr, SPC 5848, Ann Arbor, MI 48109 5848, USA
    Expert Opin Pharmacother 10:1953-63. 2009
  4. ncbi request reprint Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma
    Rashmi Chugh
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Cancer 109:2315-22. 2007
  5. doi request reprint Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma
    Scott M Schuetze
    Division of Hematology Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI 48109 5848, United States
    Eur J Cancer 48:1347-53. 2012
  6. doi request reprint Dose--effect relationships for femoral fractures after multimodality limb-sparing therapy of soft-tissue sarcomas of the proximal lower extremity
    Daniel Pak
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
    Int J Radiat Oncol Biol Phys 83:1257-63. 2012
  7. ncbi request reprint Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma
    Rashmi Chugh
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    J Clin Oncol 23:3597-604. 2005
  8. doi request reprint Undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: a novel highly aggressive soft tissue tumor with distinctive histopathology
    Eun Young Karen Choi
    Departments of Pathology Internal Medicine Orthopedic Surgery, University of Michigan, Ann Arbor, MI
    Am J Surg Pathol 37:1379-86. 2013
  9. ncbi request reprint Chordoma: the nonsarcoma primary bone tumor
    Rashmi Chugh
    Department of Internal Medicine, Division of Hematology Oncology, 24 Frank Lloyd Wright Drive, A3400, P O Box 483, Ann Arbor, Michigan 48106, USA
    Oncologist 12:1344-50. 2007
  10. doi request reprint Ewing sarcoma of the kidney: case series and literature review of an often overlooked entity in the diagnosis of primary renal tumors
    R Grant Rowe
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109 5848, USA
    Urology 81:347-53. 2013

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model
    Rashmi Chugh
    1500 E Medical Center Dr, C407 Med Inn, SPC 5843, Ann Arbor, MI 48109 5843, USA
    J Clin Oncol 27:3148-53. 2009
    ..Although rare dramatic responses were seen, imatinib is not an active agent in advanced sarcoma in these subtypes...
  2. doi request reprint Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial
    Rashmi Chugh
    Department of Internal Medicine, University of Michigan, Ann Arbor, 48109 5843, USA
    Clin Cancer Res 16:4884-91. 2010
    ..Here, we report specifically on the outcome of patients with AF as well as evaluations undertaken to examine the mechanism of imatinib...
  3. doi request reprint Pharmacotherapy of sarcoma
    Rashmi Chugh
    University of Michigan, C407 Med Inn Building, 1500 E Medical Center Dr, SPC 5848, Ann Arbor, MI 48109 5848, USA
    Expert Opin Pharmacother 10:1953-63. 2009
    ..The clinical and biologic heterogeneity of the > 50 histologic subtypes of sarcomas often require different therapeutic approaches...
  4. ncbi request reprint Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma
    Rashmi Chugh
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Cancer 109:2315-22. 2007
    ..The pharmacokinetics of ifosfamide and CYP3A measurements observed are reported...
  5. doi request reprint Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma
    Scott M Schuetze
    Division of Hematology Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI 48109 5848, United States
    Eur J Cancer 48:1347-53. 2012
    ..The combination of sirolimus and cyclophosphamide demonstrated synergistic anti-sarcoma activity in preclinical models; therefore, we conducted a phase II trial of sirolimus and cyclophosphamide in patients with advanced sarcoma...
  6. doi request reprint Dose--effect relationships for femoral fractures after multimodality limb-sparing therapy of soft-tissue sarcomas of the proximal lower extremity
    Daniel Pak
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
    Int J Radiat Oncol Biol Phys 83:1257-63. 2012
    ..We investigated the clinical and dosimetric predictors for radiation-associated femoral fractures in patients with proximal lower extremity soft tissue sarcomas (STS)...
  7. ncbi request reprint Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma
    Rashmi Chugh
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    J Clin Oncol 23:3597-604. 2005
    ....
  8. doi request reprint Undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: a novel highly aggressive soft tissue tumor with distinctive histopathology
    Eun Young Karen Choi
    Departments of Pathology Internal Medicine Orthopedic Surgery, University of Michigan, Ann Arbor, MI
    Am J Surg Pathol 37:1379-86. 2013
    ..8 months. CIC-DUX4 sarcoma represents a novel translocation-associated sarcoma with distinctive histopathologic features and rapid disease progression. ..
  9. ncbi request reprint Chordoma: the nonsarcoma primary bone tumor
    Rashmi Chugh
    Department of Internal Medicine, Division of Hematology Oncology, 24 Frank Lloyd Wright Drive, A3400, P O Box 483, Ann Arbor, Michigan 48106, USA
    Oncologist 12:1344-50. 2007
    ..Radiation therapy may also salvage some patients with local recurrence. One series reported a 2-year actuarial local control rate of 33% for patients treated with proton beam irradiation...
  10. doi request reprint Ewing sarcoma of the kidney: case series and literature review of an often overlooked entity in the diagnosis of primary renal tumors
    R Grant Rowe
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109 5848, USA
    Urology 81:347-53. 2013
    ..To evaluate our own experience with primary Ewing sarcoma family tumors (ESFTs) of the kidney and to review cases of this in published reports...
  11. doi request reprint Risk factors for local recurrence and metastasis in soft tissue sarcomas of the extremity
    Aaron Sabolch
    University of Michigan Medical School, Ann Arbor, USA
    Am J Clin Oncol 35:151-7. 2012
    ....
  12. ncbi request reprint Experimental therapies and clinical trials in bone sarcoma
    Rashmi Chugh
    Division of Hematology Oncology, University of Michigan, Ann Arbor, Michigan 48109 5843, USA
    J Natl Compr Canc Netw 8:715-25. 2010
    ..This article discusses recently completed and currently enrolling clinical trials for the 3 most common bone sarcomas: osteosarcoma, Ewing's sarcoma family tumors, and chondrosarcoma...
  13. ncbi request reprint Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma
    Francis P Worden
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    J Clin Oncol 23:105-12. 2005
    ..The purpose of this study was to compare the efficacy and toxicity of doxorubicin with high-dose (HD) ifosfamide or standard-dose (SD) ifosfamide in patients with STS...
  14. ncbi request reprint Nonepithelial malignancies of the breast
    Rashmi Chugh
    Department of Internal Medicine, Cancer Center University of Michigan, Ann Arbor, Michigan 48109, USA
    Oncology (Williston Park) 18:665-73; discussion 673-6. 2004
    ..This review discusses various features of these uncommon malignancies and their treatment, with the goal of increasing understanding of their clinical behavior and management...